UMIN-CTR Clinical Trial

UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials


Recruitment status Completed
Unique ID issued by UMIN UMIN000028023
Receipt No. R000032055
Scientific Title PrasugrEl moNotherapy after DrUg eLUting stent deployMent as a Management Of patients who are uNsuitable for lOng-term dual antiplatelet therapy
Date of disclosure of the study information 2017/07/01
Last modified on 2021/01/12

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments

Basic information
Public title PrasugrEl moNotherapy after DrUg eLUting stent deployMent as a Management Of patients who are uNsuitable for lOng-term dual antiplatelet therapy
Acronym PENDULUM mono
Scientific Title PrasugrEl moNotherapy after DrUg eLUting stent deployMent as a Management Of patients who are uNsuitable for lOng-term dual antiplatelet therapy
Scientific Title:Acronym PENDULUM mono

Condition Patient who underwent placement of a drug elution stent by percutaneous coronary intervention, have a high bleeding risk, and are considered to have a medical difficulty in receiving long-term administration of Aspirin
Classification by specialty
Classification by malignancy Others
Genomic information NO

Narrative objectives1 To evaluate the incidence of bleeding events and cardiovascular events in patients receiving Prasugrel monotherapy without concomitant Aspirin after percutaneous coronary intervention (PCI) with implantation of a DES, who have high risk of bleeding, and who is not medically preferable to administrate Aspirin concomitantly for long-term.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1 Others
Trial characteristics_2 Others
Developmental phase Not applicable

Primary outcomes The incidence of BARC type 2, 3, and 5 bleeding events from Month 1 to 12 after index PCI.
Key secondary outcomes To examine the incidence of events in the following A and B from Month 1 to 12 after index PCI.
A. Bleeding events (each category in accordance with the BARC criteria, major bleeding and minor bleeding in the TIMI criteria)
B. Cardiovascular events (all-cause death, cardiovascular death, non-lethal myocardial infarction, non-lethal stroke, non-lethal cerebral infarction, revascularization (TVR, TLR), transient ischemic attack (TIA), stent thrombosis, and peripheral artery occlusion)
To examine the primary outcome (Bleeding in BARC 2,3 and 5 criteria) and secondary outcomes described above during the following evaluation periods in 1 to 3.
<Evaluation period>
1. From 1 month to 24 months after PCI
2. During 12 months after PCI
3. During 24 months after PCI

Study type Others,meta-analysis etc

Study design
Basic design
Randomization unit
Dynamic allocation
Institution consideration

No. of arms
Purpose of intervention
Type of intervention

Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria Patients are included in this study if all of the following criteria are met:
1. Patients 20 years of age or older at the time of informed consent
2. Patients who are indicated for PCI with drug eluting stent (Patients would be judged by referring product-package insert.)
3. Patients who are planned to be treated with prasugrel more than 12 months after PCI with drug eluting stent
4. Patients who satisfy at least one of the followings, and who is not medically preferable to administrate Aspirin concomitantly for long-term.
(1) Complication of peptic ulcer
(2) Having a history of bleeding (e.g., intracranial hemorrhage such as cerebral hemorrhage, pulmonary hemorrhage, gastrointestinal hemorrhage, ocular fundus bleeding)
(3) Having a bleeding tendency (e.g., concurrent anemia, a hemoglobin level of less than 11 g/dL before PCI)
(4) Having renal impairment (e.g., concurrent renal failure, dialysis, eGFR of less than 60 before PCI)
(5)Continuous administration of nonsteroidal anti-inflammatory agents (NSAIDs) (other than Aspirin) after PCI is required
(6)Continuous administration of oral anticoagulants (OACs) after PCI is required
(7)Elderly (at least 75 years old when informed consent is obtained)
(8) low body weight (<50kg)
(9)Other patients who are considered to have a bleeding risk (Reason must be specified.)
5. Patients who have provided written consent to participate in the study (When emergency, patients would be asked to agree to participate in clinical study after their agent has agreed to do so.)
Key exclusion criteria Patients are excluded from the study if any one of the following criteria is met:
1. Patients who requires dual antiplatelet therapy (DAPT) for at least 6 months from the viewpoint of a thrombotic risk
2. Bleeding patients (e.g., hemophilia, intracranial hemorrhage, gastrointestinal hemorrhage, urinary tract hemorrhage, hemoptysis, vitreous hemorrhage)
3. Patients who underwent PCI in coronary artery bypass graft as the target lesion(s)
4. Patients who are participating or plan to participate in a clinical study or clinical research requiring intervention for the choice of antiplatelet therapy before the end of follow-up in this study
5. Patients who are participating in the clinical study titled: Platelet rEactivity in patieNts with DrUg eLUting stent and balancing risk of bleeding and ischeMic event (PENDULUM registry, UMIN000020332)
Target sample size 1100

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Masato Nakamura
Organization Toho University Ohashi Medical Center
Division name Division of Cardiovascular Medicine
Zip code
Address 2-17-6 Ohashi, Meguro, Tokyo, Japan
TEL 03-3468-1251

Public contact
Name of contact person
1st name
Middle name
Last name Masashi Odani
Organization CMIC Co., Ltd.
Division name Academia Clinical Research Div.
Zip code
Address Hamamatsucho Bldg., 1-1-1 Shibaura, Minato-ku, Tokyo, Japan
TEL 03-6779-8172
Homepage URL

Institute Toho University Ohashi Medical Center

Funding Source
Organization Daiichi Sankyo Co., LTD
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor Daiichi Sankyo Co., LTD
Name of secondary funder(s) No

IRB Contact (For public release)

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2


Other administrative information
Date of disclosure of the study information
2017 Year 07 Month 01 Day

Related information
URL releasing protocol
Publication of results Partially published

URL related to results and publications
Number of participants that the trial has enrolled 1222
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Recruitment status Completed
Date of protocol fixation
2017 Year 05 Month 19 Day
Date of IRB
2017 Year 05 Month 31 Day
Anticipated trial start date
2017 Year 07 Month 25 Day
Last follow-up date
2020 Year 12 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other related information This trial is a non-randomized, prospective registry study.
In principal, investigators will obtain informed consent from patients or their legally acceptable representatives before index PCI, and they will consecutively enroll patients who meet the inclusion criteria, but not the exclusion criteria.

Management information
Registered date
2017 Year 06 Month 30 Day
Last modified on
2021 Year 01 Month 12 Day

Link to view the page

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name

Contact us.